禁用毛面假体预防BIA-ALCL是否合理:荟萃分析与成本效果研究
该研究采用决策树模型评估光面假体相比毛面假体在隆胸术中预防BIA-ALCL的成本效果。模型参数来自已发表文献,包膜挛缩率通过荟萃分析计算。结果显示光面假体避免BIA-ALCL的增量成本为18,562,003美元,增量成本效果比为负值,敏感性分析提示仅在BIA-ALCL风险≥1:196且光面假体包膜挛缩概率≤0.096时具有成本效果。结论认为禁用毛面假体预防BIA-ALCL并非成本效果策略。
要点
- 光面假体避免BIA-ALCL的增量成本为18,562,003美元。
- 敏感性分析:BIA-ALCL风险≥1:196且光面假体包膜挛缩概率≤0.096时具成本效果。
- 禁用毛面假体需权衡光面假体更高的包膜挛缩率和再手术率。
核心结论
- 使用光面假体预防BIA-ALCL不具有成本效果。
- 禁用毛面假体预防BIA-ALCL可能带来额外后果,需结合光面假体更高的包膜挛缩率和再手术率来考量。
研究设计与样本
- 研究采用决策树模型进行成本效果分析,模型输入参数来自已发表文献。
- 包膜挛缩率通过荟萃分析计算。
- 效果指标包括生命年、避免BIA-ALCL、避免死亡和避免再手术,并进行了敏感性分析。
主要发现
- 光面假体相比毛面假体避免BIA-ALCL的增量成本为18,562,003美元。
- 生命年、避免死亡和避免再手术的增量成本效果比均为负值。
- 敏感性分析显示,避免1例BIA-ALCL,光面假体在BIA-ALCL风险等于或大于1:196且光面假体包膜挛缩概率等于或小于0.096时具有成本效果。
关键数值与推荐
- 避免BIA-ALCL的增量成本为18,562,003美元(光面假体 vs 毛面假体)。
- 生命年、避免死亡和避免再手术的增量成本效果比为负值。
- 成本效果阈值:BIA-ALCL风险≥1:196且光面假体包膜挛缩概率≤0.096。
临床怎么用
- 临床决策中应权衡光面假体与毛面假体在BIA-ALCL风险和包膜挛缩/再手术风险之间的平衡。
- 禁用毛面假体前需考虑光面假体可能增加的包膜挛缩率和再手术率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an emergent disease that threatens patients with texturized breast implants. Major concerns about the safety of these implants are leading to global changes to restrict the utilization of this product. The principal alternative is to perform breast augmentation utilizing smooth implants, given the lack of association with BIA-ALCL. The implications and costs of this intervention are unknown. OBJECTIVES: The authors of this study determined the cost-effectiveness of smooth implants compared with texturized implants for breast augmentation surgery. METHODS: A tree decision model was utilized to analyze the cost-effectiveness. Model input parameters were derived from published sources. The capsular contracture (CC) rate was calculated from a meta-analysis. Effectiveness measures were life years, avoided BIA-ALCL, avoided deaths, and avoided reoperations. A sensitivity analysis was performed to test the robustness of the model. RESULTS: For avoided BIA-ALCL, the incremental cost was $18,562,003 for smooth implants over texturized implants. The incremental cost-effectiveness ratio was negative for life years, and avoided death and avoided reoperations were negative. The sensitivity analysis revealed that to avoid 1 case of BIA-ALCL, the utilization of smooth implants would be cost-effective for a risk of developing BIA-ALCL equal to or greater than 1:196, and there is a probability of CC with smooth implants equal to or less than 0.096. CONCLUSIONS: The utilization of smooth implants to prevent BIA-ALCL is not cost-effective. Banning texturized implants to prevent BIA-ALCL may involve additional consequences, which should be considered in light of higher CC rates and more reoperations associated with smooth implants than with texturized implants.
引用
- Danilla SV, Jara RP, Miranda F, et al. Is Banning Texturized Implants to Prevent Breast Implant-Associated Anaplastic Large Cell Lymphoma a Rational Decision? A Meta-Analysis and Cost-Effectiveness Study. Aesthet Surg J. 2020. PMID: 31761953. doi:10.1093/asj/sjz343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。